Clinical trials
Breast Cancer (Triple Negative Breast Cancer (TNBC)) clinical trials
Below are recruiting breast cancer (triple negative breast cancer (tnbc)) clinical trials, each written for real people, not researchers. We’re tracking 254 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05377996RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors with tumor tissue testing
This early-stage study tests emiltatug leda-dotin (Emi-Le) in people with advanced or recurring solid cancers. It aims to see how the drug works and how safely it can be given, using tumor tissue testing to help understand who may benefit.
Phoenix, ArizonaAges 18 years+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT05208762RecruitingPhase 1
PD-L1 antibody drug study for advanced lung and head/neck cancers
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
Birmingham, AlabamaAges 18 years+ - NCT05192798RecruitingPhase 2
Albumin-bound chemo plus anti-blood-vessel drugs for TNBC
This Phase 2 study tests a chemotherapy called albumin-bound paclitaxel combined with medicines that block new blood vessel growth (antiangiogenic agents) for women with recurrent or metastatic triple-negative breast cancer. It aims to see whether this combination can better control cancer when it comes back or has spread.
Bengbu, AnhuiAges 18–80 - NCT05111561RecruitingPhase 1
Testing a two-drug combo for RAS-mutant or triple negative breast cancer
This study tests a combination of two new drugs, ZEN003694 and binimetinib, for people with advanced solid tumors that have certain gene changes (like RAS mutations) or triple negative breast cancer. The goal is to see if this combination can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT05076760RecruitingPhase 1
Study of a cancer-killing virus with standard treatments
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
Tampa, FloridaAges 18 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
Gilbert, ArizonaAges 18 years+ - NCT04959474Recruiting
Pre-surgery radiation study with or without calorie restriction
This trial looks at whether a planned calorie-reduction diet before surgery can change how early breast cancer responds to a short course of radiation. It may help people understand if diet could improve outcomes alongside standard pre-surgery treatment.
Philadelphia, PennsylvaniaAges 40 years+ - NCT04861077RecruitingEarly Phase 1
PET/MRI monitoring for PD-L1–positive triple-negative breast cancer
This early-phase study uses advanced PET/MRI scans to monitor how immunotherapy treatment works in people with triple-negative breast cancer that is PD-L1 positive. It may help doctors better track tumor changes in the body over time.
Birmingham, AlabamaAges 18–75 - NCT04683679RecruitingPhase 2
Radiation plus pembrolizumab and olaparib for certain breast cancers
This study tests whether adding the drugs pembrolizumab and olaparib (or similar “radiosensitizers”) to radiation can improve outcomes for women with advanced breast cancer that is triple-negative or ER-positive/Her2-negative. It’s designed for cancers that have spread or come back and where radiation is being considered to control disease.
Basking Ridge, New JerseyAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Studying a new drug for cancers with a specific TP53 change
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
Irvine, CaliforniaAges 12 years+ - NCT04529044RecruitingPhase 2
177Lu-DOTATATE for advanced breast cancer with targeted receptors
This Phase 2 trial tests whether 177Lu-DOTATATE can slow or shrink stage IV or recurrent breast cancer. It targets tumor “receptors” found on scans, using a radioactive medicine that delivers radiation directly to cancer cells.
Portland, OregonAges 18–100 - NCT04468061RecruitingPhase 2
Study chemo drug plus immunotherapy for metastatic triple-negative breast cancer
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
Stamford, ConnecticutAges 18 years+ - NCT04434040RecruitingPhase 2
Atezolizumab and sacituzumab to prevent breast cancer return
This trial tests two medicines after surgery and chemotherapy to help lower the risk that triple-negative breast cancer comes back. It’s for people whose cancer still showed “residual” invasive disease after neoadjuvant (before-surgery) chemotherapy, and whose blood test shows traces of tumor DNA.
San Francisco, CaliforniaAges 18 years+ - NCT04333706RecruitingPhase 1/Phase 2
Sarilumab plus capecitabine for certain breast cancers
This trial studies whether adding sarilumab to capecitabine can shrink or control metastatic or high-risk breast cancer that lacks HER2 and is either triple-negative or hormone-resistant. It aims to find a safe dose first, then look at how well the treatment works compared with historical results.
Los Angeles, CaliforniaAges 18–99 - NCT04348747RecruitingPhase 2
Vaccine plus pembrolizumab for breast cancer in the brain
This trial studies whether a personalized immune-cell vaccine (dendritic cell vaccine) combined with pembrolizumab can help control brain metastases from certain types of breast cancer. It may help your immune system better recognize and attack cancer cells in the brain.
Tampa, FloridaAges 18 years+ - NCT04230109RecruitingPhase 2
Sacituzumab Govitecan for newly diagnosed TNBC
This trial tests a drug called sacituzumab govitecan for people with newly diagnosed triple-negative breast cancer (TNBC) that hasn't been treated yet. The drug targets cancer cells directly to try to stop them from growing.
Boston, MassachusettsAges 18 years+ - NCT03606967RecruitingPhase 2
Individualized vaccine added to standard treatment for metastatic triple-negative breast cancer
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
Orange, CaliforniaAges 18 years+ - NCT02926690RecruitingPhase 1
MELK inhibitor safety study for advanced breast cancer
This Phase 1 study tests how safe a drug called an MELK inhibitor is in people with advanced breast cancer that has spread or cannot be removed with surgery. If you qualify, the study is focused on side effects and includes a special group for triple-negative breast cancer.
Norwalk, ConnecticutAges 18 years+ - NCT01042379RecruitingPhase 2
Adaptive drug trial for newly diagnosed breast cancer
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
Birmingham, AlabamaAges 18 years+ - NCT07066917Recruiting
Breast cancer treatment response study
This study looks at how well newer treatments work for advanced or metastatic breast cancer and why some people respond better than others. It is for anyone with HR-positive, HER2-positive/low, or triple-negative breast cancer who has started at least one treatment cycle.
AthensAges 18 years+ - NCT07020780Recruiting
Short-course radiation for high-risk breast cancer
This trial tests a short, more intense radiation schedule for women with certain breast cancer types or who are under 40. It aims to reduce treatment time while still targeting the whole breast and any high-risk areas.
MilanAges 18–70 - NCT06105684RecruitingPhase 2
Low-dose capecitabine for advanced breast cancer
This trial tests a lower dose of the chemotherapy drug capecitabine in people with advanced breast cancer that is HER2 negative. It aims to see if this gentler dose works well, especially for older or frailer patients who may have more difficulty with standard treatment.
Birmingham, AlabamaAges 60 years+
Hear when a new Breast Cancer (Triple Negative Breast Cancer (TNBC)) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer (triple negative breast cancer (tnbc))?
- Yes. Clin2 currently lists 254 recruiting breast cancer (triple negative breast cancer (tnbc)) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer (triple negative breast cancer (tnbc)) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer (triple negative breast cancer (tnbc)) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.